Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiff LexingtonCDIX +0.79%27 EV-to-EBITDA is -62.00 as of Aug. 11, 2026. GuruFocus rates CDIX with a GF Score™ of 27/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 513 Healthcare Providers & Services companies, Cardiff Lexington ranks worse than 194931.58% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cardiff Lexington's enterprise value is $39.24 Mil.
Cardiff Lexington's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.63 Mil. Therefore, Cardiff Lexington's EV-to-EBITDA for today is -62.00.
The historical rank and industry rank for Cardiff Lexington's EV-to-EBITDA or its related term are showing as below:
CDIX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -13183.66 Med: 20.64 Max: 3996.93
Current: -62
During the past 13 years, the highest EV-to-EBITDA of Cardiff Lexington was 3996.93. The lowest was -13183.66. And the median was 20.64.
CDIX's EV-to-EBITDA is ranked worse than 100% of 513
companies
in the Healthcare Providers & Services industry
Industry Median: 10.9
vs CDIX: -62.00
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cardiff Lexington's PE Ratio (TTM) for today is calculated as:
Cardiff Lexington's share price for today is $0.51.
Cardiff Lexington's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Cardiff Lexington's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Cardiff Lexington's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Lexington EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cardiff Lexington's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cardiff Lexington's EV-to-EBITDA falls into.
Cardiff Lexington's current Enterprise Value is $39.24 Mil.
Cardiff Lexington's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Lexington (CDIX) has a EV-to-EBITDA of -62.00 as of Aug. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cardiff Lexington. According to the industry distribution chart, Cardiff Lexington ranks #999999 out of 513 companies in the Healthcare Providers & Services industry.
Is Cardiff Lexington's EV-to-EBITDA too high?
Cardiff Lexington's current EV-to-EBITDA is -62.00. Based on the distribution chart, Cardiff Lexington ranks #999999 out of 513 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Cardiff Lexington has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Lexington's EV-to-EBITDA compare to AMS and SYRA?
According to the Healthcare Providers & Services industry distribution chart, Cardiff Lexington ranks #999999 out of 513 companies for EV-to-EBITDA. This places Cardiff Lexington in the lower half of its industry. The industry median EV-to-EBITDA is 10.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.90, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cardiff Lexington. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiff Lexington's current EV-to-EBITDA is -62.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Lexington stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Lexington (CDIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.51 — trading 537.5% above its estimated fair value. The current EV-to-EBITDA is -62.00. Cardiff Lexington's overall GF Score™ is 27/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cardiff Lexington (CDIX), the current EV-to-EBITDA is -62.00 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardiff Lexington (CDIX) Overvalued in 2026?
Based on GuruFocus' analysis, Cardiff Lexington stock appears to be overvalued.
The current stock price of $0.51 is trading 537.5% above its estimated GF Value™ of $0.08.
GuruFocus considers Cardiff Lexington to be Significantly Overvalued.
Key valuation signals for CDIX:
EV-to-EBITDA: -62.00
GF Value™: $0.08 vs. price of $0.51 (537.5% above fair value)
No single metric tells the full story. See the CDIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardiff Lexington Corp is an acquisition holding company, conducting its operations through its operating subsidiaries. The company has two reportable operating segments; Healthcare (Nova), and Real Estate (Edge View). The Healthcare segment generates all of the company's revenue and provides a full range of diagnostic and surgical services for injuries and disorders of the skeletal system and associated bones, joints, tendons, muscles, ligaments, and nerves. The Real estate segment consists of Edge View, a real estate company that owns various acres zoned medium-density residential.
27GF Score
Get the complete analysis for CDIX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CDIX has been successfully added to your 
